DE60329070D1 - Antikörper gegen den fibroblastenwachstumsfaktor 23 - Google Patents
Antikörper gegen den fibroblastenwachstumsfaktor 23Info
- Publication number
- DE60329070D1 DE60329070D1 DE60329070T DE60329070T DE60329070D1 DE 60329070 D1 DE60329070 D1 DE 60329070D1 DE 60329070 T DE60329070 T DE 60329070T DE 60329070 T DE60329070 T DE 60329070T DE 60329070 D1 DE60329070 D1 DE 60329070D1
- Authority
- DE
- Germany
- Prior art keywords
- ferm
- amino acid
- antibody
- acid sequence
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 102000004042 Fibroblast Growth Factor-23 Human genes 0.000 title abstract 3
- 108090000569 Fibroblast Growth Factor-23 Proteins 0.000 title abstract 3
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 5
- 230000000694 effects Effects 0.000 abstract 2
- 210000004408 hybridoma Anatomy 0.000 abstract 2
- 230000004060 metabolic process Effects 0.000 abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 229910019142 PO4 Inorganic materials 0.000 abstract 1
- 229930003316 Vitamin D Natural products 0.000 abstract 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 abstract 1
- 238000007792 addition Methods 0.000 abstract 1
- 125000000539 amino acid group Chemical group 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 230000002860 competitive effect Effects 0.000 abstract 1
- 230000037430 deletion Effects 0.000 abstract 1
- 238000012217 deletion Methods 0.000 abstract 1
- 230000003053 immunization Effects 0.000 abstract 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 abstract 1
- 239000010452 phosphate Substances 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
- 235000019166 vitamin D Nutrition 0.000 abstract 1
- 239000011710 vitamin D Substances 0.000 abstract 1
- 150000003710 vitamin D derivatives Chemical class 0.000 abstract 1
- 229940046008 vitamin d Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Cell Biology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2001401689 | 2001-12-28 | ||
| JP2002262020 | 2002-09-06 | ||
| PCT/JP2003/000017 WO2003057733A1 (fr) | 2001-12-28 | 2003-01-06 | Anticorps diriges contre le facteur de croissance 23 des fibroblastes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE60329070D1 true DE60329070D1 (de) | 2009-10-15 |
Family
ID=26625414
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60329070T Expired - Lifetime DE60329070D1 (de) | 2001-12-28 | 2003-01-06 | Antikörper gegen den fibroblastenwachstumsfaktor 23 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US7923012B2 (de) |
| EP (1) | EP1466925B1 (de) |
| JP (1) | JP4527982B2 (de) |
| KR (1) | KR101016476B1 (de) |
| CN (1) | CN100519584C (de) |
| AT (1) | ATE441666T1 (de) |
| AU (1) | AU2003202472B2 (de) |
| CA (1) | CA2471656C (de) |
| DE (1) | DE60329070D1 (de) |
| ES (1) | ES2331414T3 (de) |
| HK (1) | HK1078093A1 (de) |
| WO (1) | WO2003057733A1 (de) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4799801B2 (ja) * | 2000-08-11 | 2011-10-26 | 協和発酵キリン株式会社 | リン酸代謝、カルシウム代謝、石灰化及びビタミンｄ代謝を調節するポリペプチド並びにそれをコードするｄｎａ |
| DE60329070D1 (de) | 2001-12-28 | 2009-10-15 | Kyowa Hakko Kirin Co Ltd | Antikörper gegen den fibroblastenwachstumsfaktor 23 |
| WO2007011896A2 (en) * | 2005-07-18 | 2007-01-25 | The Trustees Of Boston University | Method to inhibit proliferation and growth of metastases |
| WO2007126924A1 (en) * | 2006-03-28 | 2007-11-08 | University Of South Carolina | Method for stimulating proteoglycan synthesis in cells |
| US20100062984A1 (en) * | 2007-01-25 | 2010-03-11 | Rajiv Kumar | Fgf-23 polypeptides |
| US7883705B2 (en) | 2007-02-14 | 2011-02-08 | Kyowa Hakko Kirin Co., Ltd. | Anti FGF23 antibody and a pharmaceutical composition comprising the same |
| WO2009133905A1 (ja) * | 2008-04-28 | 2009-11-05 | 協和発酵キリン株式会社 | ヒト線維芽細胞増殖因子23（ヒトfgf23)の作用を抑制するペプチドおよびそれを含む医薬組成物 |
| WO2011121306A1 (en) | 2010-03-31 | 2011-10-06 | Stabilitech Ltd. | Stabilisation of viral particles |
| BR112012025047A2 (pt) | 2010-03-31 | 2016-06-21 | Stabilitech Ltd | formulações líquidas estabilizadas |
| WO2012029837A1 (ja) * | 2010-08-31 | 2012-03-08 | 協和メデックス株式会社 | 線維芽細胞増殖因子－２３の測定方法及び測定試薬 |
| WO2012055096A1 (zh) * | 2010-10-27 | 2012-05-03 | 温州医学院生物与天然药物开发中心有限公司 | 抗fgf-23抗体的制备方法及用途 |
| TW201250248A (en) | 2011-04-25 | 2012-12-16 | Kyowa Medex Co Ltd | Prognostication method of renal failure |
| GB201117233D0 (en) * | 2011-10-05 | 2011-11-16 | Stabilitech Ltd | Stabilisation of polypeptides |
| US20140273031A1 (en) * | 2013-03-15 | 2014-09-18 | The Cleveland Clinic Foundation | In-vitro method for monoclonal antibody production |
| GB201406569D0 (en) | 2014-04-11 | 2014-05-28 | Stabilitech Ltd | Vaccine compositions |
| PL3151859T3 (pl) | 2014-06-09 | 2021-07-26 | Ultragenyx Pharmaceutical Inc. | Efektywna i skuteczna kontrola stężenia fosforanów w surowicy dla optymalnego tworzenia kości |
| CN104502596A (zh) * | 2014-12-23 | 2015-04-08 | 温州医科大学 | 一种慢性肾病诊断试剂盒 |
| CN105699664A (zh) * | 2015-04-13 | 2016-06-22 | 陈柏龄 | Fgf23检测试剂盒及其制备方法 |
| US11244760B2 (en) | 2015-06-25 | 2022-02-08 | Karydo Therapeutix, Inc. | Prediction device based on inter-organ cross talk system |
| CL2015003047A1 (es) * | 2015-10-15 | 2016-06-17 | Univ Chile | Método ex vivo para detectar precozmente injuria renal aguda en pacientes críticos, que comprende la mediciom en una muestra de tres proteinas como biomarcadores, factor de crecimiento fibroblástico 23, klotho y eritropoyetina |
| JP2019082329A (ja) * | 2016-03-14 | 2019-05-30 | 協和メデックス株式会社 | 慢性腎臓病患者における高リン血症の発症のしやすさを試験する方法 |
| CN109414504B (zh) * | 2016-03-29 | 2022-04-08 | 无限生物制药公司 | 药物组合物或食品组合物及评价活性成分体内效果的方法 |
| EP3438282A4 (de) | 2016-03-29 | 2020-05-06 | Advanced Telecommunications Research Institute International | Screening-verfahren auf geeignete substanzen für eine aktive komponente zur vorbeugung oder behandlung von mindestens einer krankheit, die aus der gruppe aus renaler unterfunktion, chronischer nierenerkrankung und nierenversagen ausgewählt wurde |
| GB2562241B (en) | 2017-05-08 | 2022-04-06 | Stabilitech Biopharma Ltd | Vaccine compositions |
| JP7296875B2 (ja) * | 2017-05-31 | 2023-06-23 | ミナリスメディカル株式会社 | 線維芽細胞増殖因子－２３の測定方法、測定試薬及び測定キット |
| JP7445288B2 (ja) * | 2017-08-01 | 2024-03-07 | Ｋａｒｙｄｏ ＴｈｅｒａｐｅｕｔｉＸ株式会社 | 皮膚のバイオマーカー |
| WO2021128065A1 (zh) * | 2019-12-25 | 2021-07-01 | 广州菲康生物技术有限公司 | 人fgf-23的荧光免疫层析试纸和人fgf-23的荧光免疫层析检测试剂盒 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1985003934A1 (en) | 1984-03-06 | 1985-09-12 | Takeda Chemical Industries, Ltd. | Chemically modified protein and process for its preparation |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| NZ226694A (en) | 1987-10-28 | 1994-04-27 | Oncogen | Human immunoglobulin produced by recombinant dna techniques |
| JP2958019B2 (ja) | 1988-05-06 | 1999-10-06 | 住友製薬株式会社 | ポリエチレングリコール誘導体、修飾ペプチドおよびその製造方法 |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5958879A (en) | 1989-10-12 | 1999-09-28 | Ohio University/Edison Biotechnology Institute | Growth hormone receptor antagonists and methods of reducing growth hormone activity in a mammal |
| US6001358A (en) | 1995-11-07 | 1999-12-14 | Idec Pharmaceuticals Corporation | Humanized antibodies to human gp39, compositions containing thereof |
| US20020102604A1 (en) | 1999-12-08 | 2002-08-01 | Milne Edwards Jean-Baptiste Dumas | Full-length human cDNAs encoding potentially secreted proteins |
| TWI227734B (en) | 1998-05-18 | 2005-02-11 | Univ London | A novel polypeptide hormone phosphatonin |
| TWI255853B (en) | 1998-08-21 | 2006-06-01 | Kirin Brewery | Method for modifying chromosomes |
| WO2000060085A1 (en) | 1999-04-02 | 2000-10-12 | Millennium Pharmaceuticals, Inc. | Fibroblast growth factor-20 |
| US6596849B1 (en) | 1999-05-28 | 2003-07-22 | Academia Sinica | Monoclonal-antibody for analysis and clearance of polyethylene glycol and polyethylene glycol-modified molecules |
| JP2004522402A (ja) | 1999-06-02 | 2004-07-29 | ジェネンテック・インコーポレーテッド | 同一のものをコードする分泌及び膜貫通ポリペプチドと核酸 |
| CA2491433A1 (en) | 1999-12-01 | 2001-06-07 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| JP2003518944A (ja) * | 2000-01-05 | 2003-06-17 | ザイモジェネティクス，インコーポレイティド | 新規ｆｇｆ相同体ｚｆｇｆ１２ |
| US20030149238A1 (en) | 2000-02-14 | 2003-08-07 | Pankaj Agarwal | Novel compounds |
| JP2005508131A (ja) * | 2000-02-15 | 2005-03-31 | アムジェン インコーポレイテッド | 線維芽細胞成長因子−２３分子およびその使用 |
| US20060160181A1 (en) | 2000-02-15 | 2006-07-20 | Amgen Inc. | Fibroblast Growth Factor-23 molecules and uses thereof |
| US20020082205A1 (en) | 2000-03-08 | 2002-06-27 | Nobuyuki Itoh | Human FGF-23 gene and gene expression products |
| US20030105302A1 (en) * | 2000-03-08 | 2003-06-05 | Nobuyuki Itoh | Human FGF-23 gene and gene expression products |
| JP2004504063A (ja) | 2000-07-19 | 2004-02-12 | アドバンスド リサーチ ＆ テクノロジー インスティテュート | 新規線維芽細胞増殖因子（ｆｇｆ２３）および使用方法 |
| JP4799801B2 (ja) | 2000-08-11 | 2011-10-26 | 協和発酵キリン株式会社 | リン酸代謝、カルシウム代謝、石灰化及びビタミンｄ代謝を調節するポリペプチド並びにそれをコードするｄｎａ |
| CA2430013C (en) | 2000-11-30 | 2011-11-22 | Medarex, Inc. | Transgenic transchromosomal rodents for making human antibodies |
| WO2002076467A1 (en) | 2001-03-22 | 2002-10-03 | Genzyme Corporation | Compositions and methods to regulate bone and mineral metabolism |
| US20040171825A1 (en) | 2001-04-26 | 2004-09-02 | Lydie Bougueleret | Human fibroblast growth factor-related compositions |
| DE60329070D1 (de) | 2001-12-28 | 2009-10-15 | Kyowa Hakko Kirin Co Ltd | Antikörper gegen den fibroblastenwachstumsfaktor 23 |
| US7094551B2 (en) | 2002-09-17 | 2006-08-22 | Zahradnik Richard J | Immunoassays, assay methods, antibodies and method of creating antibodies for detecting FGF-23 |
| US20090151011A1 (en) | 2005-01-21 | 2009-06-11 | Kirin Pharma Kabushiki Kaisha | Chimeric Non-Human Animal and Use Thereof |
| US20100062984A1 (en) | 2007-01-25 | 2010-03-11 | Rajiv Kumar | Fgf-23 polypeptides |
| US7883705B2 (en) | 2007-02-14 | 2011-02-08 | Kyowa Hakko Kirin Co., Ltd. | Anti FGF23 antibody and a pharmaceutical composition comprising the same |
-
2003
- 2003-01-06 DE DE60329070T patent/DE60329070D1/de not_active Expired - Lifetime
- 2003-01-06 EP EP03701009A patent/EP1466925B1/de not_active Expired - Lifetime
- 2003-01-06 JP JP2003558047A patent/JP4527982B2/ja not_active Expired - Lifetime
- 2003-01-06 CA CA2471656A patent/CA2471656C/en not_active Expired - Lifetime
- 2003-01-06 WO PCT/JP2003/000017 patent/WO2003057733A1/ja active Application Filing
- 2003-01-06 AU AU2003202472A patent/AU2003202472B2/en not_active Expired
- 2003-01-06 CN CNB038048574A patent/CN100519584C/zh not_active Expired - Lifetime
- 2003-01-06 AT AT03701009T patent/ATE441666T1/de not_active IP Right Cessation
- 2003-01-06 KR KR1020047010142A patent/KR101016476B1/ko active Protection Beyond IP Right Term
- 2003-01-06 ES ES03701009T patent/ES2331414T3/es not_active Expired - Lifetime
- 2003-01-06 US US10/500,296 patent/US7923012B2/en not_active Expired - Lifetime
-
2005
- 2005-11-10 HK HK05110064.5A patent/HK1078093A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| HK1078093A1 (en) | 2006-03-03 |
| CN1639193A (zh) | 2005-07-13 |
| ES2331414T3 (es) | 2010-01-04 |
| EP1466925A4 (de) | 2006-01-04 |
| KR101016476B1 (ko) | 2011-02-24 |
| KR20040073518A (ko) | 2004-08-19 |
| ATE441666T1 (de) | 2009-09-15 |
| CA2471656A1 (en) | 2003-07-17 |
| AU2003202472B2 (en) | 2009-11-26 |
| US7923012B2 (en) | 2011-04-12 |
| EP1466925B1 (de) | 2009-09-02 |
| US20050048058A1 (en) | 2005-03-03 |
| JP4527982B2 (ja) | 2010-08-18 |
| CN100519584C (zh) | 2009-07-29 |
| WO2003057733A1 (fr) | 2003-07-17 |
| EP1466925A1 (de) | 2004-10-13 |
| JPWO2003057733A1 (ja) | 2005-05-19 |
| AU2003202472A1 (en) | 2003-07-24 |
| CA2471656C (en) | 2012-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60329070D1 (de) | Antikörper gegen den fibroblastenwachstumsfaktor 23 | |
| CY1112833T1 (el) | Καινοφανης προσδετης της κυτοκινης ζcυτοr17 | |
| ATE390441T1 (de) | Niedrigallergene proteinvarianten | |
| DK0839196T3 (da) | Humant CTLA-8 og anvendelser af CTLA-8-relaterede proteiner | |
| NO20074516L (no) | Pattedyrcytokinlignende polypeptid-1 | |
| DK1114156T3 (da) | Transformerende vækstfaktor Beta-9 (ZTGFSS9) fra pattedyr | |
| ATE482272T1 (de) | Zytokinproteinfamilie | |
| CA2441187A1 (en) | Acetyllysine-recognizing monoclonal antibody and process for producing the same | |
| AU2003202489A1 (en) | Screening method | |
| DE69941961D1 (de) | Monoklonale Antikörper gegen humane Thymidylat-Synthase und Hybridomen zu derer Herstellung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |